Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E2.69 EPS (ttm)3.09 Insider Own21.22% Shs Outstand44.04M Perf Week7.91%
Market Cap383.97M Forward P/E- EPS next Y-1.90 Insider Trans-0.53% Shs Float36.36M Perf Month11.98%
Income132.33M PEG- EPS next Q-0.51 Inst Own56.90% Short Float5.90% Perf Quarter20.58%
Sales250.01M P/S1.54 EPS this Y-166.33% Inst Trans0.50% Short Ratio2.82 Perf Half Y-17.30%
Book/sh5.37 P/B1.55 EPS next Y3.72% ROA51.83% Short Interest2.15M Perf Year15.88%
Cash/sh5.00 P/C1.66 EPS next 5Y- ROE89.61% 52W Range6.06 - 14.34 Perf YTD-1.42%
Dividend Est.- P/FCF5.14 EPS past 5Y- ROI52.22% 52W High-41.98% Beta0.96
Dividend TTM- Quick Ratio4.96 Sales past 5Y316.32% Gross Margin98.22% 52W Low37.29% ATR (14)0.59
Dividend Ex-Date- Current Ratio4.96 EPS Y/Y TTM397.60% Oper. Margin27.39% RSI (14)56.17 Volatility11.89% 5.87%
Employees162 Debt/Eq0.09 Sales Y/Y TTM511.18% Profit Margin52.93% Recom1.43 Target Price15.33
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q304.11% Payout- Rel Volume2.82 Prev Close8.97
Sales Surprise336.50% EPS Surprise532.53% Sales Q/Q5910.39% EarningsFeb 28 AMC Avg Volume761.51K Price8.32
SMA207.64% SMA503.45% SMA200-5.85% Trades Volume2,068,344 Change-7.25%
Date Action Analyst Rating Change Price Target Change
Jan-02-24Upgrade Wells Fargo Equal Weight → Overweight $14
May-10-23Initiated Truist Buy $18
Mar-10-23Initiated Oppenheimer Outperform $14
Oct-07-21Upgrade Robert W. Baird Neutral → Outperform $6 → $9
Feb-26-21Downgrade Robert W. Baird Outperform → Neutral $18 → $6
Feb-03-21Downgrade Wedbush Outperform → Neutral $6
Feb-03-21Downgrade BTIG Research Buy → Neutral
Dec-24-20Downgrade Cantor Fitzgerald Overweight → Neutral $15 → $10
Dec-23-20Downgrade Raymond James Outperform → Mkt Perform
Nov-11-20Downgrade Oppenheimer Outperform → Perform
Feb-29-24 11:09AM
Feb-28-24 04:41PM
07:00AM Loading…
Feb-26-24 07:00AM
Feb-21-24 07:00AM
Feb-20-24 07:00AM
Feb-07-24 07:00AM
Jan-11-24 10:09PM
Jan-04-24 10:45PM
Jan-03-24 11:15AM
Jan-02-24 04:07PM
01:51PM Loading…
Dec-17-23 12:03PM
Dec-08-23 10:13AM
Dec-07-23 06:10AM
Dec-06-23 07:00AM
Nov-07-23 10:16AM
Nov-06-23 05:22PM
07:00AM Loading…
Oct-30-23 07:00AM
Sep-25-23 07:00AM
Sep-07-23 04:01PM
Aug-30-23 07:00AM
Aug-22-23 08:14AM
Aug-08-23 04:01PM
Aug-07-23 08:00AM
Aug-03-23 08:25AM
Aug-02-23 07:00AM
Jul-27-23 07:00AM
Jul-14-23 05:40AM
Jul-11-23 08:53PM
Jul-10-23 08:00AM
Jun-21-23 04:49AM
Jun-15-23 06:30AM
Jun-01-23 07:52PM
May-25-23 12:29PM
May-18-23 06:00AM
May-09-23 08:35AM
May-05-23 06:08AM
May-03-23 10:25PM
May-02-23 04:30PM
Apr-08-23 09:12AM
Mar-28-23 07:00AM
Mar-12-23 08:04AM
Mar-08-23 03:03AM
Mar-07-23 08:25AM
Mar-06-23 07:00AM
Feb-28-23 07:00AM
Feb-13-23 08:00AM
Feb-10-23 06:23AM
Feb-09-23 07:00AM
Feb-03-23 04:36AM
Feb-02-23 06:43AM
Jan-27-23 07:00AM
Jan-24-23 04:01PM
Jan-20-23 12:08PM
Jan-09-23 01:23PM
Jan-04-23 07:00AM
Dec-21-22 06:57AM
Dec-14-22 07:00AM
Nov-29-22 04:01PM
Nov-10-22 05:26AM
Nov-08-22 08:25AM
Nov-01-22 07:30AM
Oct-27-22 10:02AM
Oct-25-22 10:01AM
Oct-18-22 04:01PM
Oct-14-22 08:34AM
Oct-11-22 07:00AM
Oct-04-22 11:34AM
Oct-03-22 07:00AM
Sep-27-22 07:00AM
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sandrock AlfredPresident and CEOFeb 21Sale7.4613,03397,226334,954Feb 22 04:34 PM
Swartz RobinChief Operating OfficerFeb 21Sale7.453,96629,547118,361Feb 22 04:36 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerFeb 21Sale7.463,76428,079175,669Feb 22 04:32 PM
Carter Todd AlfredChief Scientific OfficerFeb 21Sale7.473,36525,13787,627Feb 22 04:30 PM
Carter Todd AlfredChief Scientific OfficerFeb 20Sale7.686024,62390,992Feb 22 04:30 PM
Swartz RobinChief Operating OfficerJan 17Sale7.152,54318,18272,327Jan 19 04:34 PM
Carter Todd AlfredChief Scientific OfficerJan 17Sale7.181,2669,09053,094Jan 19 04:32 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerOct 03Sale6.9913,56794,833149,433Oct 05 04:41 PM
Carter Todd AlfredChief Scientific OfficerSep 15Option Exercise2.855,00014,25064,860Sep 18 04:44 PM
Carter Todd AlfredChief Scientific OfficerSep 15Sale8.1610,50085,68054,360Sep 18 04:44 PM
Carter Todd AlfredChief Scientific OfficerJul 06Sale10.805,50059,40059,860Jul 10 04:42 PM
Sandrock AlfredPresident and CEOApr 03Sale7.837,43758,232214,618Apr 05 05:04 PM
Swartz RobinChief Operating OfficerApr 03Sale7.831,2599,85871,617Apr 05 05:02 PM
Hesslein Robert W.Senior VP & General CounselMar 20Sale7.764,41034,222102,200Mar 22 04:47 PM
Swartz RobinChief Operating OfficerMar 20Sale7.763,65428,35572,876Mar 22 04:48 PM
Carter Todd AlfredChief Scientific OfficerMar 20Sale7.762,19317,01865,360Mar 22 04:49 PM
Swartz RobinChief Operating OfficerMar 15Sale8.2015,373126,05976,530Mar 17 04:37 PM